Özet
ALS, which is diagnosed in 1500 to 4500 people every year in our country, is a fa-tal neurodegenerative disease manifested by progressive loss of muscle function. Glutamate excitotoxicity and genetic factors are seen as the most critical factors in the pathogenesis of this disease, where individuals cannot even meet their own basic needs day by day. Although research on many symptomatic and therapeutic drugs continues, only FDA-approved riluzole and edaravone are included in the treatment protocol. In addition, cell-based therapies and phytotherapy are also used to prevent and treat the disease, improve symptoms and increase the quality of life of patients. In this study, the pathogenesis of ALS disease, its treatment, and the development of the treatment were included, the treatment potentials of drugs were examined and an evaluation was prepared to guide future studies.
Tercüme edilen katkı başlığı | Pathophysiology and Treatment Approaches of Amyotrophic Lateral Sclerosis |
---|---|
Orijinal dil | Türkçe |
Sayfa (başlangıç-bitiş) | 50-69 |
Sayfa sayısı | 20 |
Dergi | Hacettepe University Journal of the Faculty of Pharmacy |
Hacim | 43 |
Basın numarası | 1 |
DOI'lar | |
Yayın durumu | Yayınlanan - 3 Oca 2023 |
Harici olarak yayınlandı | Evet |
Keywords
- Amyotrophic lateral sclerosis
- neurodegeneration
- pathogenesis
- riluzole